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Background: Bone metastases represent a common and severe complication in breast cancer, and the involvement of cancer
stem cells (CSCs) in the promotion of bone metastasis is currently under discussion. Here, we used a human-in-mice model to
study bone metastasis formation due to primary breast CSCs-like colonisation.
Methods: Primary CD44þCD24 breast CSCs-like were transduced by a luciferase-lentiviral vector and injected through
subcutaneous and intracardiac (IC) routes in non-obese/severe-combined immunodeficient (NOD/SCID) mice carrying
subcutaneous human bone implants. The CSCs-like localisation was monitored by in vivo luciferase imaging. Bone metastatic
CSCs-like were analysed through immunohistochemistry and flow cytometry, and gene expression analyses were performed by
microarray techniques.
Results: Breast CSCs-like colonised the human-implanted bone, resulting in bone remodelling. Bone metastatic lesions were
histologically apparent by tumour cell expression of epithelial markers and vimentin. The bone-isolated CSCs-like were CD44
CD24þ and showed tumorigenic abilities after injection in secondary mice. CD44CD24þ CSCs-like displayed a distinct bone
tropism signature that was enriched in genes that discriminate bone metastases of breast cancer from metastases at other organs.
Conclusion: Breast CSCs-like promote bone metastasis and display a CSCs-like bone tropism signature. This signature has clinical
prognostic relevance, because it efficiently discriminates osteotropic breast cancers from tumour metastases at other sites.
Breast tumours are characterised by phenotypic heterogeneity.
They are composed of different groups of cells that display a
remarkable variability in many phenotypic traits, including
different metastatic abilities and survival ability after therapy.
The cancer stem cell (CSC) hypothesis, which suggests that the
variety between functionally important properties of individual
cells arises from differences in their differentiation status, may
explain the intra-tumour heterogeneity seen in breast tumours
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(Campbell and Polyak, 2007; Shackleton et al, 2009). Cancer stem
cells are defined as a subset of tumour-initiating cells that share
surface markers with somatic stem/progenitor cells of their tissue
of origin. They are able to self-renew, proliferate and differentiate
to give rise to a heterogeneous tumour cell population (Clarke and
Fuller, 2006; Rosen and Jordan, 2009). In breast cancer, CSCs are
identified as a rare population of CD44þCD24 epithelial-specific
antigenlow cells that show in vivo tumorigenicity based on
xenotransplantation assays in non-obese/severe-combined immu-
nodeficient (NOD/SCID) mice (Al-Hajj et al, 2003; Shipitsin et al,
2007).
Breast cancer cells are known to have a peculiar bone tropism;
indeed, 70% of breast cancer patients develop bone metastases
(Mundy, 2002). The metastatic process sometimes occurs very
early in the natural history of the disease but can occur at later
stages. In either case, once the tumour has spread to the bone, the
cancer is no longer curable (Mundy and Sterling, 2008). Recent
reports highlighted the molecular mechanisms underlying the
dissemination of breast cancer cells in bone and led to the
identification of discrete sets of osteotropic genes associated with
bone tropism (Kang et al, 2003; Minn et al, 2005; Liu et al, 2007;
van den Hoogen et al, 2010). Evidence that CSCs are responsible
for bone metastasis is still not conclusive owing to the difficulties in
isolating CSCs and the lack of a valid animal model (Liu et al, 2010;
van den Hoogen et al, 2010; Buijs et al, 2011).
This study investigates the ability of non-metastatic human
breast CSCs to metastasise to bone. A NOD/SCID-human-in-mice
model was utilised to inject CD44þCD24 CSCs-like, isolated
from a non-bone metastatic primary breast cancer (Kuperwasser
et al, 2005; Roato et al, 2010). These mice were implanted
subcutaneously (SC) with a fragment of human bone to establish a
human microenvironment. Injected breast CD44þCD24 CSCs-
like acquired the ability to metastasise the implanted bone and
switched to a CD44CD24þ phenotype while maintaining
tumorigenic abilities in vivo. The CD44CD24þ CSCs isolated
from bone expressed a signature of significant enrichment of sets
of genes biologically relevant in the process of cancer dissemina-
tion that persisted at subsequent passages in the absence of
surrounding bone tissue (Subramanian et al, 2005). This signature
derived from CSCs is relevant for clinical prognosis because it
efficiently discriminates osteotropic breast cancers from tumours
metastasising to other sites.
MATERIALS AND METHODS
Breast CSCs. Breast CSCs were previously isolated and char-
acterised for the expression of stemness markers, showing a
CD44þCD24 phenotype, and for tumorigenic potential
(Bussolati et al, 2009). Tumour specimens were obtained from a
consenting patient, according to the ethics committee of the San
Giovanni Battista Hospital of Torino, Italy. The histological
analysis showed a HER2-negative lobular-infiltrating carcinoma
of the pleomorphic type, expressing the oestrogen receptor in
B60% of cells. As previously described (Bussolati et al, 2009), the
cell suspension obtained from the tumour tissue was processed,
and mammospheres were derived. These mammospheres were
studied for their ability to metastasise to bone as patients with
breast cancer frequently develop bone metastases (Smid et al,
2008). CD44þCD24 CSCs-like were transduced with a lucifer-
ase-lentiviral expression vector, originating Luc-CSCs-like. Both
breast CSCs-like and Luc-CSCs-like were injected in mice to rule
out possible modifications of the tumorigenic phenotype due to
lentiviral transduction.
Human-in-mice model of bone metastasis induced by breast
CSCs. Experimental animals were treated in compliance with the
actual national and international guidelines (the Italian legislative
decree 116/92 and the European Community Directive 86/609
CEE) and in accordance with the authorisation provided by the
Italian Ministry of Health (as of DM 44/1994-A and subsequent
integrations). All of the orthotopic xenograft models were
established in NOD/SCID mice as previously described (Roato
et al, 2010). A fresh fragment of human bone obtained from the
discarded femoral head of an adult patient submitted to total joint
replacement (after the patient’s informed consent) was trans-
planted SC in the left flank of 15 NOD/SCID 5-week-old female
mice (Charles River Laboratories Italia, Calco, Italy). In six 5-week-
old mice, breast CSCs-like (three mice) and Luc-CSCs-like (three
mice) were injected SC close to the bone implant. In another six
mice, CSCs-like (three mice) and Luc-CSCs-like (three mice) were
injected by an IC route to demonstrate the actual capability of
CSCs to metastasise to bone. For SC injections, 1.5 105 breast
CSCs were resuspended in PBS and Matrigel 1 : 3 (BD Biosciences,
Bedford, MA, USA), and injected in a volume of 40ml using a
25-gauge needle. For the IC route, 1 103 CSCs-like were injected
in the left ventricle. The development of tumour masses and
metastases to bone and other organs was monitored by in vivo
imaging system (IVIS) for 45 days after the injection. In order to
evaluate secondary tumour generation, mammospheres obtained
from the metastatic lesion in human-implanted bone were cultured
for 1 week. Maintenance of the CSC phenotype was confirmed by
flow cytometry for the expression of CD44 and CD24, and then the
cells were re-injected into another six mice (three SC and three IC)
with the same experimental conditions indicated above. The
presence of circulating human IgG in mice sera was demonstrated
by human IgG ELISA, purchased by ICL Inc. (Ankara, Turkiye).
Lentivirus production and breast CSCs-like transduction. Vec-
tor stocks were produced by transient transfection of the luciferase
transfer plasmid, the packaging plasmids pMDLg/pRRE and
pRSV.REV, and the vesicular stomatitis virus (VSV) envelope
plasmid pMD2.VSV-G (15, 6.5, 2.5 and 3.5 mg, respectively, for 10-
cm dishes) in 293T. After 12–14 h, the transfection solution was
removed, and the cells were washed twice with 1 PBS. The
media was replaced and collected after 24 h. The viral supernatants
were filtered using a 0.45-mm low-protein-binding filter flask
(Millipore, Vimodrone, Italy), and viral particles were concentrated
by ultracentrifugation as described (Follenzi et al, 2000).
Determination of the viral p24 antigen concentration was done
by HIV-1 p24 Core profile ELISA (PerkinElmer Life, Waltham,
MA, USA).
Breast CSCs were resuspended in Opti-MEM in the presence of
8 mgml 1 polybrene (Sigma-Aldrich, St. Louis, MO, USA) and
plated in 96-well round-bottom plates. Then, high-titer lentiviruses
(210 ng of p24 gag equivalent particles) were added to the cells, and
the cells were incubated for 4 h.
Breast Luc-CSCs-like were tested for luciferase expression by
using the Luciferase Assay System (Promega Corp., Madison, WI,
USA), as described in the protocol kit. Briefly, the cells were rinsed
with PBS and lysed with RLB lysis buffer by performing a single
freeze-thaw cycle. Twenty microlitres of cell lysate was added to a
luminometer tube containing the luciferase assay reagent and read
by performing a2-s measurement delay followed by a 10-s
measurement read for luciferase activity. Importantly, we did not
observe significant differences in tumour phenotypes associated
with lentiviral transduction, as demonstrated by histological
appearance, flow cytometry analysis (see Supplementary Figure
S2A and B) and microarray analysis of parental breast CSCs-like
and Luc-CSCs-like.
In vivo bioluminescence imaging. For the bioluminescence
imaging (BLI), mice were anaesthetised by isoflurane inhalation
and were subsequently intraperitoneally injected with 200 ml of
15mgml 1 D-luciferin (Caliper Life Science, Hopkinton, MA,
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USA). The bioluminescence signals were monitored using the IVIS
system 2000 series (Xenogen Corp., Alameda, CA, USA) consisting
of a highly sensitive cooled CCD camera. Two kinetic biolumi-
nescent acquisitions were collected between 0 and 20min after D-
luciferin injection to confirm the peak photon emission, which was
recorded as maximum photon efflux per second; imaging times
ranged from 1 to 60 s, depending on the amount of luciferase
activity. Data were analysed using the total photon flux emission
(photons s 1) in the regions of interest defined manually. At
various time points after tumour implantation (25, 35 and 45
days), the mice were imaged using the IVIS 2000 system.
Isolation of bone metastatic cells. To isolate metastatic cells
from the osteolytic lesions, human-implanted bone was retrieved,
finely minced and then digested by incubation for 30min at 37 1C
in DMEM containing collagenase I (Sigma-Aldrich). After
collagenase neutralisation, the cells were washed by Hank’s
balanced saline solution (Lonza, Basel, Switzerland), and red
blood cells were lysed with Red Blood cell Lysis Solution
(Promega Corp.). The cell suspension was forced through a
graded series of meshes to separate the cell components from the
stroma and aggregates. After filtration, single cells were plated in
a serum-free DMEM-F12 selective medium (Gibco, Invitrogen,
Monza, Italy) supplemented with 10 ngml 1 basic fibroblast
growth factor, 20 ngml 1 epidermal growth factor (EGF;
PeproTech, London, UK), 5 mgml 1 insulin and 0.4% bovine
serum albumin (Sigma-Aldrich) to avoid the presence of non-
neoplastic contaminating cells. After 1 week, the appearance of
non-adherent spherical clusters of cells, that is, mammospheres,
was observed. Mammospheres were collected on the bottom of a
conical tube by spontaneous precipitation to remove nonliving
cells. After 5 days, mammospheres were collected by gentle
centrifugation and disaggregated with a Non-enzymatic Cell
Dissociation Solution (Sigma-Aldrich). In order to analyse the
phenotype of these bone-derived mammospheres, the dissociated
cells were counted and stained for flow cytometry analysis with
anti-human CD44PE and CD24FITC (BD Pharmingen, Bedford,
MA, USA). For every antibody, we also used the relative isotype
control. Samples were analysed in a FACs Calibur instrument and
elaborated by Flowjo (Tree Star, Ashland, OR, USA).
Immunohistochemistry and histological analysis. Immunohis-
tochemistry was performed on tissues fixed in 10% neutral-
buffered formalin, and bone tissues were decalcified with EDTA
treatment until soft. Tissues were embedded in paraffin, sections
were deparaffinised, rehydrated through graded alcohols and
subjected to antigen retrieval for immunohistochemistry. Sections
were stained for H&E for morphological study. The presence of
human vessels was demonstrated by staining for anti-CD34, clone
QbndN/10 (NeoMarkers, Freemont, CA, USA), whereas tumour
cells were stained by mouse monoclonal antibodies against low
molecular weight cytokeratins (CK AE1/AE3, clone AE1/AE3/
PCK26), epithelial membrane antigen (EMA, clone E29) and
vimentin (clone R9) from DAKO (Glostrup, Denmark), and CD44
(clone C26) and CD24 (clone ML5) from BD Pharmingen. To
identify the collagen fibres on the new bone, a trichrome stain was
performed by Gomori’s trichrome stain kit (DAKO). TRAP staining
was performed to identify osteoclasts, according to the manufac-
turer’s instructions (Roche, Basel, Switzerland).
Cancer stem cell RNA extraction and microarray analysis. Total
RNA was extracted with the miRNeasy Mini Kit (Qiagen, Milano,
Italy). The cells were collected as a pellet, homogenised directly in
QIAzol Lysis Reagent (a maximum of 107 cells in 0.7ml of reagent)
and processed according to the manufacturer’s protocol. RNA
quality control was performed on a Bioanalyzer 2100 (Agilent,
Berkshire, UK). Biotinylated antisense RNA (aRNA) was prepared
from 500 ng of total RNA using the Illumina RNA Amplification
Kit (Ambion, Austin, TX, USA), according to the manufacturer’s
directions, and quality control was performed on a Bioanalyzer 2100
(Agilent). Labelled aRNA was hybridised on Illumina HumanHT-12
v4 expression BeadChips for 16h. Hybridised BeadChips were
subsequently washed, stained with streptavidin-Cy3 and scanned on
a BeadStation 500 (Illumina, San Diego, CA, USA).
Microarray data analysis. Raw microarray data were processed
and analysed with the GenomeStudio software (Illumina),
according to standard procedures. Briefly, bead-level data
were summarised and cubic spline normalised. Samples were
subsequently organised into the following groups: (i) breast
CSCs-like, CD44þCD24 , (duplicate); (ii) Luc-CSCs-like,
CD44þCD24,(singlicate); (iii) bone-isolated metastatic CSCs-
like, CD44CD24þ , (duplicate). Subsequently, the samples were
(iv) grown in vitro as spheroids (singlicate) or (v) re-grown in
subcutaneous implants (duplicate). The ‘Illumina Custom’ variant
of the t-test implemented in GenomeStudio was employed to
select genes with differential expression between breast CSCs-like
and bone-isolated metastatic CD44CD24þ CSCs-like, (P-
valueo0.001, fold-change43). This resulted in 860 probes being
selected (of which 710 were upregulated and 150 were down-
regulated in bone metastases). Subsequently, probes were filtered
to remove those showing differential expression (fold-
change41.5) between breast CSCs-like and Luc-CSCs-like. This
filter reduced upregulated probes to 480 and downregulated
probes to 100. Finally, the up- and downregulated probes were
tested for their maintenance of change (more than two-fold)
compared with breast CSCs-like and derivatives of bone-isolated
metastatic CD44CD24þ CSCs-like, that is, spheroids and
subcutaneous implants. Ninety-six upregulated and 23 down-
regulated probes corresponding to 88 and 22 genes, respectively,
passed this final filter and collectively defined the breast CSCs-
like bone tropism signature (see Supplementary Table S3).
Hierarchical clustering was performed using the GEDAS software
(Fu and Medico, 2007). The breast cell line microarray data set
was generated by Kang et al (2003) and obtained as
Supplementary Material on the publisher’s website. The breast
cancer metastasis data set generated by Zhang et al (2009) was
retrieved from the Gene Expression Omnibus database (GSE14020).
GSE14020 is a composite of two sub-data sets obtained with two
different Affymetrix array types (Santa Clara, CA, USA). To
homogenise them, the data were cross-mapped based on probe-
sets and scaled on median expression. Gene set enrichment analysis
(GSEA; Mootha et al, 2003; Subramanian et al, 2005) on our
expression data filtered for detection was performed online using the
Broad Institute application (http://www.broadinstitute.org/gsea/
msigdb/downloads.jsp). Genes represented by multiple probes were
collapsed to the probe with the maximum value. From the Molecular
Signatures Database of GSEA, we selected the collections C2
(curated gene sets; file: c2.v3.symbols.gmt) and C5 (Gene Ontology;
file: c5.v3.symbols.gmt) for analysis. Enrichment statistics were
performed with default settings and the Signal_to_Noise metric with
1000 permutations. Gene set enrichment analysis considering the
CSCs-like bone tropism signature as a gene set was run on published
data sets (Kang et al, 2003; Zhang et al, 2009) to test for enrichment
in genes with differential expression between bone metastatic vs
non-metastatic cells or tissues. The gene set enrichment score was
calculated from the ‘Ratio_of_classes’ score for the genes in the set,
and the FDR was evaluated with 1000 permutations.
Serum detection of IL-6, IL-8 and CCL20. To analyse the
expression of human IL-6, IL-8 and CCL20 in mice, we utilised
the multi-analyte detection system Milliplex Map, according to
the manufacturer’s instructions. Molecule detection was per-
formed with the instrument Luminex 200 (Luminex Corporation,
Austin, TX, USA), and data were analysed through the
MILLIPLEX analyst software.
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RESULTS
Breast CSCs-like show tumorigenic and metastatic character-
istics in the human-in-mice model. To verify the ability of breast
CSCs-like to metastasise bone, we utilised CSCs-like previously
isolated from a primary breast tumour. These cells were CD44þ
CD24 , grew as mammospheres and expressed the stem cells
markers Oct-4 and nestin, but not the differentiation markers
CK14, CK18 and a-SMA. They grew in SCID mice and were able
to generate serial tumours when re-injected into other mice
(Bussolati et al, 2009). After isolation from the primary tumour,
these breast CSC cells were injected SC or through an IC route in
NOD/SCID mice carrying a small piece of human bone previously
implanted in a flank. The introduction of human bone in mice
allowed us to study in a species-specific manner the interaction
between breast CSCs-like and the bone microenvironment. Before
the SC and IC injection, we transduced these breast CSCs-like
through a luciferase-lentiviral vector (Luc-CSCs-like) in order to
monitor their localisation in vivo. The number of mice in the
experimental groups, mice survival, percentages of bone engraft-
ment, and bone and lung metastases are indicated in
Supplementary Table S1. To analyse the intensity of the luciferase
signal released from Luc-CSCs-like, increasing amounts of Luc-
CSCs were plated in a multiwell plate and subjected to IVIS
imaging. We determined a luciferase signal starting from 5 102
cells, and its intensity was roughly proportional to the different cell
dilutions (Supplementary Figure S1). After the Luc-CSCs-like
SC injection, we monitored the tumour growth at different time
points for 45 days. Twenty days after Luc-CSCs-like injection, the
primary tumours were macroscopically evident and bone localisa-
tions were detectable (Figure 1A). The intensity of the signal in
the bone increased progressively over the course of the study,
eventually becoming stronger in the bone than in the tumour mass
(Figure 1B and C). This result was confirmed by the quantification
of the mean luciferase intensity in the bone and in the SC
tumour mass, which showed a higher value in the bone than in SC
masses, particularly at day 45, Po0.05 (Figure 1D). These data
confirm our hypothesis that breast CSCs-like show osteotropism
and indicate that the human bone microenvironment is a
particularly favourable soil because their number significantly
increased in bone. In 5 out of 12 mice, we detected lung metastases
at day 20, at which point the animals were killed before the
occurrence of bone lesion formation (see also Supplementary
Figure S2 and Supplementary Table S1). We also tested the
bone metastatic ability of the subpopulation of CD44 /CD24þ
cells and found that they did not metastasise to bone (data not
shown).
Breast CSCs-like metastasise human bone. To rule out meta-
stasis of our breast CSCs-like to mice bone, we performed X-rays
on the mice, and we did not detect lesions in mice bone
(Supplementary Figure S3). To verify the validity of our human-
in-mice model, we needed to analyse the viability of the implanted
bone in mice. The bone implants were viable because little-to-no
necrosis was evident in the grafts and bone marrow cells,
mineralised areas and stromal cells, and neo-vascularisation was
present (Figure 2A). The engraftment of the human bone was also
demonstrated by the newly synthesised bone present in the control
(Figure 2B). Neo-vascularisation was present, and vessels expressed
human CD34, ruling out the presence of murine vessels in the bone
implants (Figure 2C). Breast CSCs-like colonised the human-
implanted bone; a large area of invading tumour cells was
evident and live bone was remodelled after both IC and SC
injection (Figure 2D and E, respectively). The marked increase
in bone remodelling due to bone metastases was evaluated
through trichrome staining, which showed a large area of new
bone apposition (Figure 2F). In detail, the area of neo-apposition
was lower (blue stain) in the controls (Figure 2B) than that in
the bone invaded by breast CSCs-like (Figure 2F). Moreover,
we detected a lower number of TRAP-positive osteoclasts in the
controls (Figure 2G) than that in bone with metastatic lesions
(Figure 2H). These results demonstrate an increase in bone
remodelling due to metastasis of the CSCs-like. To demonstrate the
human bone marrow activity in the implanted bone, we measured
human IgG in the serum of mice and detected a medium level of
80 mgml 1 (data not shown).
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Figure 1. Bioluminescence imaging (BLI). (A) Tumour growth was examined by BLI. Luc-CSCs-like were injected SC into flank of the SCID mice.
Representative images of two animals after different time points (20, 35, and 45 days after SC injection) are shown. (B) At day 20, the SC tumour
mass is clearly evident, whereas the bone localisation is detectable only in one mice (arrow). (C) At day 35, an increased tumour volume and
invasion to human bone becomes particularly evident (arrow). (D) At 45 days, the signal derived from bone localisation of the CSCs-like is stronger
in bone than that in SC tumour mass.
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The bone-isolated metastatic cells show a phenotypic switch. To
analyse the phenotype of breast CSCs-like injected in mice and
retrieved from tumour masses and bone lesions, we utilised both
FACS analysis and histological investigation for the expression of
CD44 and CD24. The injected breast CSCs-like were CD44þ
CD24 (96%±3.2%) (Figure 3B, see also Supplementary Figure
S4), but after their bone retrieval they mainly showed a CD44
CD24þ phenotype (40%±4.1%; Figure 3C). The analysis of
primary tumour masses demonstrated that they were mainly
constituted of CD44þCD24 cells (Figure 4A–D), whereas the
bone lesions were mainly constituted of CD44CD24þ cells
(Figure 4E–H). These data confirm the FACS results and
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Figure 2. Histological analysis of the implanted bone. (A) H&E-stained section in control mice shows the presence of human live bone, blood
vessels, newly synthesised bone with osteoblasts lining cells, as indicated by the arrows (magnification 40). (B) Trichrome staining shows in blue
the new collagen fibres in the bone: osteoid originated after the bone implanted in SC of the control mice. (C) Human endothelial cells in the
blood vessels are stained for anti-human CD34, as indicated by the arrows. (D and E, respectively) Breast Luc-CSCs-like metastasise the human-
implanted bone after IC and SC injection, in both cases area of pathological bone resorption are evident, as indicated by the arrows. (F) A marked
neo-bone apposition is evident (osteoid is indicated by the blue staining) in bone invaded by breast CSCs-like. Osteoclasts stained for TRAP in
bone of control mice (G) and mice injected with breast CSCs-like (H).
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suggest a phenotypic switch of the injected CD44þCD24 cells,
likely induced by the bone microenvironment. The CD44
CD24þ cells present in the bone lesions also expressed low
molecular weight CKs, EMA and vimentin (Figure 5A–C). This
expression of both epithelial and mesenchymal markers suggests
that CD44CD24þ cells have the capability to perform the
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Figure 3. Phenotype of parental breast CSCs-like and bone-isolated CSCs-like. Representative dot plots show the isotipic control (A), the
CD44þCD24 breast CSCs-like injected in mice (B) and the bone-isolated CSCs-like, which express a CD44CD24þ phenotype (C).
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Figure 4. CD44 and CD24 expression in tumour mass and human-implanted bone. IHC staining of tumour masses shows tumour cells with a
CD44þCD24 phenotype (A–D). The bone-isolated CSCs-like are mainly CD44CD24þ (E–H; magnification  20 and  60).
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epithelial-to-mesenchymal (EMT) and mesenchymal-to-epithelial
transition (MET). To verify the tumorigenicity of the CD44
CD24þ bone-isolated metastatic cells, we re-injected them
in NOD/SCID mice. They showed a more aggressive growth
when injected SC than the parental CD44þCD24 cells,
because each mouse developed two or three tumour masses
(Figure 6A and B), which were constituted by cellular hetero-
geneity similar to the original tumour. Cells in the secondary
tumour mass expressed both CD44 and CD24 (Figure 6C and D),
suggesting the ability of CD44CD24þ cells to switch their
phenotype, likely through an EMT as they reacquired CD44
expression.
In order to rule out the effect of the metastatic state of these cells
on this phenotypic change, we also examined CD44 and CD24
expression in the lung metastases. Tumour cells in the lung lesions
expressed both CD44 and CD24 (Figure 7), which indicates a
A B C
EMACK VIMENTIN× 20 × 20 × 20
Figure 5. IHC analysis of CD44CD24þ bone-isolated CSCs-like. Cancer stem cells-like isolated from bone express CKs (A), EMA (B) and
vimentin (C). (Magnification  20).
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Figure 6. Analysis of secondary tumour induced by CD44CD24þ bone-isolated CSCs-like. Subcutaneous injection of CD44CD24þ cells
results in tumour mass formation, as indicated by the arrows in A. H&E staining of tumour mass (B), CD44 (C) and CD24 (D).
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different phenotype compared with the bone metastatic cells. Thus,
the phenotypic switch observed in the CD44þCD24 breast
CSCs-like seems to depend on the contact with the human-
implanted bone, underlying the importance of the bone micro-
environment in the metastatic process.
Identification of a transcriptional signature for CD44CD24þ
breast CSCs-like. Global gene expression profiling was carried out
to compare parental breast CSCs-like and Luc-CSCs-like with
bone-isolated CSCs-like. To determine whether transcriptional
changes associated with the passage in bone were stable, we also
profiled the purified CSCs-like bone-isolated metastatic cells that
were subsequently grown in vitro as mammospheres or in vivo as
subcutaneous secondary implants (see Materials and Methods for
details on the analysis). Indeed, a robust 110-gene transcriptional
signature (breast CSCs-like bone tropism signature) was found to
distinguish bone-isolated CD44CD24þ CSCs-like from parental
CD44þCD24 CSCs-like. This signature persisted after in vitro
and in vivo expansion in the absence of surrounding bone tissue.
This CSC bone tropism signature is composed of 88 upregulated
and 22 downregulated genes (96 and 23 probes, respectively, see
Supplementary Table S2), whose expression changed more than
two-fold compared with parental CSCs-like in both mammosphere
and subcutaneous derivatives of bone-isolated metastatic cells.
Seventeen of the genes in the signature were overexpressed 410-
fold, including carbonic anhydrase IX, which is known to promote
EMT and to be associated with high incidences of metastasis (Shin
et al, 2011); two chemokines, CCL20 and IL-8, involved in the
tumour metastatic process (Li et al, 2003; Beider et al, 2009);
insulin-like growth factor-binding protein 1, which is linked to
breast cancer outcome (Goodwin et al, 2002); and transcription
factor early growth response-1, which is involved in prostate
carcinoma progression and enhances IL-8 transcription and
secretion (Ma et al, 2009). We detected CCL20 at higher levels
in sera of mice with bone metastases than in that of mice without
metastases and controls (Supplementary Figure S5). IL-8 and IL-6
were detectable only in sera of mice with bone metastases
(371±65.2 and 826±597.1 pgml 1, respectively). These chemo-
kines and cytokines might be responsible for the attraction of
CSCs-like to bone and might support the phenotypic switch.
Analysis of functional modules in the breast CSCs-like bone
tropism signature. To identify differentially expressed functional
gene modules (‘gene sets’), we carried out GSEA (Subramanian
et al, 2005) utilising CD44þCD24 parental cells (breast CSCs-
like, Luc-CSCs-like), and all CD44CD24þ cell populations
derived after bone colonisation, that is, CSCs-like directly isolated
from bone lesions (two samples), subsequently grown as mammo-
spheres (one sample) or further implanted SC (two samples). Thus,
GSEA allowed us to test for permanent transcriptional features
acquired during bone colonisation. In the ‘curated gene set’
collection (C2), a total of 93 gene sets were significantly enriched
in upregulated genes (FDRo0.25 and P-valueo0.01, see also
Supplementary Table S3A). In the Gene Ontology collection
(C5), we also identified 12 upregulated gene sets (FDRo0.25
and Po0.01). The most relevant upregulated gene sets were
condensed into a specific spectrum of functional modules,
summarised in Table 1 (see also Supplementary Table S3A and B).
These modules include hypoxia response, metabolic stress, growth
factors, cytokine stimulation, chemotaxis and acid-base balance,
which are all known to be relevant to the biology of the bone
metastatic process.
Among the downregulated gene sets, 67 and 19 (for the C2 and
C5 collections, respectively) had a P-valueo0.01, but none reached
an FDRo0.25. However, the C2 gene set with the highest
downregulation enrichment was composed of genes upregulated
in brain-metastatic breast cancer (SMID_BREAST_CANCER_RE-
LAPSE_IN_BRAIN_UP). The fact that such genes are preferen-
tially downregulated in the CSCs-like bone tropism signature
supports organ specificity of the signature rather than a generic
metastatic propensity. The C5 gene set with the highest down-
regulation enrichment was ORGANELLE_ORGANIZATION and
BIOGENESIS, with a core constituted by proteins modulating the
cytoskeleton.
The breast CSCs-like bone tropism signature discriminates
osteotropic breast cancers from tumours metastasising other
sites. The ability to distinguish cell lines with different bone
tropism was tested by hierarchical clustering of a data set generated
by Kang et al (2003), in which human breast cancer cells with high
bone tropism were obtained by in vivo selection from a starting cell
line with lower bone metastatic propensity (Kang et al, 2003).
Expression data for 75 probes of this data set mapping to 51 of the
110 bone tropism genes were converted into log(2) ratio against
mean expression in all samples. Our signature was able to
A
× 20
× 60
CD24C
B
× 60
CD44
Figure 7. Analysis of CSCs-like lung metastases. (A) H&E-stained
sections of a mouse lung show the presence of a metastatic lesion,
(Magnification X 20). (B, C) IHC staining for CD44 and CD24 shows
both the markers expressed by the tumor cells. (Magnification X 60).
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segregate the strong bone metastatic cell lines from the two parental
lines from which they were derived (Figure 8A). The GSEA analysis
confirmed that the CSC bone tropism signature is significantly
enriched in genes either up- or downregulated in bone metastatic
cells vs their parental counterparts (Figure 8B, see also
Supplementary Table S2).
To verify whether the CSCs-like bone tropism signature actually
discriminates bone metastatic breast cancers from cancers with
different metastatic locations, we mapped the signature on a
published data set that includes expression profiles of 65 breast
cancer samples from metastatic lesions in the bone (n¼ 18), brain
(n¼ 22), liver (n¼ 5) and lung (n¼ 20; Zhang et al, 2009).
Expression data for 128 probes of this data set mapping to 74 of the
110 bone tropism genes were converted into log2 ratio against
mean expression in all samples and hierarchically clustered
(Figure 8C). Interestingly, the CSCs-like bone tropism signature
was able to aggregate 13 of 18 bone metastases within a cluster
where a subset of signature genes was highly expressed (top right
part of the heatmap). Metastases at other sites, such as liver, brain
and lung, were clustered in other groups. The GSEA analysis on
this data set showed significant enrichment of the CSCs-like bone
tropism signature in genes discriminating bone metastases from
metastases at other organs (Figure 8D, see also Supplementary
Table S2).
DISCUSSION
This work analysed the ability of isolated CD44þCD24 breast
CSCs-like to metastasise to human bone implanted in immuno-
compromised mice. This model was chosen because it provides a
human microenvironment, which has a key role in the growth of
metastatic cells and in their interaction with the specialised niche
in the bone marrow (Tzukerman et al, 2003; Guise, 2010).
The results of this study indicate that breast CSCs-like have a
mesenchymal and migratory CD44þCD24 phenotype and that
they are endowed with a metastatic potential to human-implanted
bone. The finding that breast CSCs-like grow in bone suggests that
breast CSCs-like encountered a particularly favourable soil in the
human-implanted bone. In the tumour masses grown SC and in
the bone lesions, the CSCs-like expressed both epithelial and
mesenchymal markers. These observations support the existence of
a migrating CSC that possesses features of both stemness and
mobility that may allow it to undergo an epithelial-to-mesench-
ymal transition (EMT) and migrate to bone. CSCs-like isolated
from the bone lesion were CD44CD24þ , indicating that they
likely performed a MET after reaching the bone, with a consequent
phenotypical switch from CD44þCD24 to CD44CD24þ ,
driven by the interaction with the bone microenvironment.
Table 1. Relevant gene sets grouped in functional modules
Functional module Gene set name Collection Size NES NOM P-value FDR q-value
MDM4 p53 target MARTORIATI_MDM4_TARGETS_FETAL_LIVER_UP C2 83 1.952 0.000 0.042
MARTORIATI_MDM4_TARGETS_NEUROEPITHELIUM_UP C2 79 1.676 0.000 0.131
Response to growth factor AMIT_EGF_RESPONSE_40_HELA C2 40 1.879 0.000 0.064
AMIT_EGF_RESPONSE_480_MCF10A C2 35 1.781 0.000 0.126
ST_ERK1_ERK2_MAPK_PATHWAY C2 26 1.775 0.000 0.121
AMIT_SERUM_RESPONSE_40_MCF10A C2 27 1.749 0.000 0.116
AMIT_EGF_RESPONSE_60_MCF10A C2 34 1.740 0.000 0.122
REACTOME_MAPK_TARGETS_NUCLEAR_EVENTS_
MEDIATED_BY_MAP_KINASES
C2 24 1.722 0.000 0.110
Cytokine stimulation CYTOKINE_METABOLIC_PROCESS C5 17 1.693 0.000 0.121
CYTOKINE_BIOSYNTHETIC_PROCESS C5 16 1.686 0.000 0.112
CYTOKINE_ACTIVITY C5 31 1.749 0.000 0.097
Angiogenesis VASCULATURE_DEVELOPMENT C5 31 1.813 0.000 0.079
ANGIOGENESIS C5 26 1.666 0.000 0.132
REGULATION_OF_ANGIOGENESIS C5 15 1.748 0.000 0.083
Hypoxia WINTER_HYPOXIA_UP C2 80 1.813 0.000 0.117
MANALO_HYPOXIA_UP C2 142 1.751 0.000 0.124
JIANG_HYPOXIA_NORMAL C2 184 1.734 0.000 0.107
HARRIS_HYPOXIA C2 61 1.731 0.000 0.106
WINTER_HYPOXIA_METAGENE C2 172 1.718 0.000 0.112
ATM target RASHI_RESPONSE_TO_IONIZING_RADIATION_1 C2 31 1.897 0.000 0.074
Histone REACTOME_TELOMERE_MAINTENANCE C2 55 1.710 0.000 0.115
Chemotaxis LOCOMOTORY_BEHAVIOR C5 31 1.595 0.000 0.176
BEHAVIOR C5 45 1.599 0.000 0.178
THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_UP C2 59 1.735 0.000 0.119
Stat3 DAUER_STAT3_TARGETS_UP C2 31 1.714 0.000 0.114
Acid-base balance CARBON_OXYGEN_LYASE_ACTIVITY C5 22 1.647 0.000 0.147
HYDRO_LYASE_ACTIVITY C5 18 1.637 0.000 0.136
Abbreviations: C2¼ curated gene collection; C5¼gene ontology collection; FDR¼ false discovery rate; NES¼ normalised enrichment score. The table reports the most relevant upregulated
gene sets (P-valueo0.01 and FDRo0.25) connected with bone metastatic process.
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Figure 8. Microarray analysis of breast CSCs-like bone tropism signature. (A) Hierarchical clustering of human breast cancer cell lines with strong
bone metastatic potential derived by parental lines in Kang et al (2003) data set, using our CSCs-like bone tropism signature composed of 110
genes (119 probes). (B) Gene set enrichment analysis samples of Kang et al (2003) for enrichment of the CSCs-like bone tropism signature in genes
that discriminate bone metastatics from parental lines. Upper panel: positive signature genes are significantly high in cells with strong metastatic
potential. Lower panel: negative signature genes are significantly low in strong metastatic potential. (C) Hierarchical clustering of 65 breast cancer
samples from metastatic lesions at different sites in a published data set, using our CSCs-like bone tropism signature. For convenience, bone
metastasis samples are highlighted by light red boxes. A subset of signature genes with significantly high expression in bone metastases is evident
in the top right corner. (D) The GSEA analysis on the metastasis samples for enrichment of the breast CSCs-like bone tropism signature
in genes that discriminate bone metastases from lesions at other sites. Left panel: positive signature genes are significantly high in bone
metastases. Right panel: negative signature genes are significantly low in bone metastases. FDR, false discovery rate; NES, normalised enrichment
score.
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Moreover, after re-injection in mice, the CD44CD24þ bone-
isolated CSCs-like formed tumour masses constituted mainly by
CD44þCD24 cells, indicating another phenotypic transition. In
different carcinomas, the importance of EMT for the induction of
stem characteristics has been demonstrated (Wellner et al, 2009;
Kong et al, 2010). The transitions between different states observed
in our CSCs-like could also be explained by a quantitative Markov
model of cell-state interconversion. According to this model, breast
cancers include discrete populations that randomly perform
transitions between states without increasing their proliferation
rate to reach a progressive equilibrium proportion (Harris et al,
2008; Gupta et al, 2011). Thus, the capability of the CD44
CD24þ bone-isolated CSCs-like to generate subcutaneous and
heterogeneous tumour masses with a high percentage of CD44þ
CD24 cells could be consistent with the attempt of these CSCs-
like to recapitulate the differentiation state heterogeneity present in
the parental tumour from which they were derived.
The phenotypic switch of breast CSCs-like could also be due to
their interaction with the haematopoietic stem cell niche.
Supporting this view is the recent report that prostate cancer cells
are able to occupy the haematopoietic stem cell niche in the bone
marrow, which is important for tumour dissemination and has a
central role in bone metastases (Shiozawa et al, 2011).
In this study, we identified for the first time a CSCs-like bone
tropism signature that can distinguish CD44CD24þ bone-
isolated CSCs-like from parental breast CD44þCD24 CSCs-like.
This signature represents a characterisation of a genetic/transcrip-
tional programme by which CSCs-like isolated from a primary
breast tumour promote bone metastasis in a human-implanted
bone. Moreover, the signature can be a proof of concept of the
phenotypic switch observed in CSCs-like after the passage in bone.
The CSCs-like bone tropism signature is characterised by genes
that are strongly upregulated, such as CCL20, IL-8 and IL-6. These
human markers were also detected in the sera of mice with bone
metastases, but not in mice without bone colonisation by CSCs-
like or control mice. It is reasonable to assume that these
chemokines and cytokines have a role in attracting CSCs-like to
the bone microenvironment and then in inducing the phenotypic
switch of the CSCs-like. Indeed, they are upregulated during the
bone invasion and retained after in vitro and in vivo passages. The
microarray analysis does highlight a strong cytokine/growth factor
transcriptional module in the CSCs-like bone tropism signature.
The upregulation of a number of functional gene modules
involved in various aspects of the bone metastatic process was
observed. A central role seems to be performed by hypoxia, which
promotes angiogenesis, bone metastasis (Dunn et al, 2009; Lu
et al, 2010), metabolic stress adaptation (Winter et al, 2007),
motility and invasiveness (Pennacchietti et al, 2003). Another set
of genes of potential interest are those involved in telomere
maintenance, which are reported to promote cancer stemness
through the expression of EGFR (Pantel and Brakenhoff, 2004;
Beck et al, 2011). In fact, the results showed upregulation of
multiple target gene sets and the Ras/ERK pathway downstream
from EGFR, which also contributes to the maintenance and
acquisition of stem-like hallmarks (Tabu et al, 2010). The
significant upregulation of ERK/MAP kinase targets suggests an
activation of proliferation, and it is likely flanked by concomitant
upregulation of genes of the MDM4 pathway, reflecting a possible
functional block of p53 (Abdel-Fatah et al, 2010). The upregula-
tion of STAT3 targets has also been identified, supporting the
role of STAT3 signalling in the growth of breast CSCs-like
(Marotta et al, 2011). Overall, these results suggest concomitant
acquisition of proliferation and stemness potential by bone-
isolated CSCs-like.
In conclusion, we demonstrated the ability of primary breast
CSCs-like to metastasise to bone by showing their direct
involvement in the pathogenesis of breast cancer bone metastasis.
Anticipating a risk of bone metastasis is mandatory because bone
metastatic recurrence often follows a period of tumour dormancy.
Identification of this CSCs-like bone tropism signature in breast
cancer patients may be a relevant prognostic factor for clinical
outcomes and may allow modification of therapeutic regimens
according to the breast cancer characteristics.
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